Regression of post-transplant Kaposi's sarcoma using sirolimus

Area of Science:

• Oncology
• Nephrology
• Immunology

Background:

• Kaposi's sarcoma (KS) is a recognized complication after solid-organ transplantation, with incidence varying geographically.
• Immunosuppressive medications are thought to reactivate human herpes virus 8, a proposed cause of post-transplant KS.
• Standard KS treatments include reducing immunosuppression, chemotherapy, and radiotherapy, but mortality remains high (8-14%).

Observation:

• A renal transplant patient developed Kaposi's sarcoma.
• The patient experienced multiple relapses despite undergoing radiotherapy.

Findings:

• Sirolimus (SRL), an immunosuppressant, possesses properties potentially beneficial for managing post-transplant tumors like KS.
• The patient responded favorably to a change in immunosuppression therapy, switching from cyclosporine to SRL.

Implications:

• Sirolimus may represent a viable therapeutic option for managing Kaposi's sarcoma in kidney transplant recipients.
• This case highlights the potential of modifying immunosuppression regimens to improve outcomes for post-transplant malignancies.